| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/26/2006 | EP1648566A2 Method for the production of flavonoid-containing compositions and use thereof |
| 04/26/2006 | EP1648564A1 Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors |
| 04/26/2006 | EP1648563A1 Carbostyril derivatives for accelerating salivation |
| 04/26/2006 | EP1648517A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 04/26/2006 | EP1648516A2 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| 04/26/2006 | EP1648515A1 Chlorthalidone combinations |
| 04/26/2006 | EP1648491A1 Use of xmp-629 for the treatment of acne |
| 04/26/2006 | EP1648484A1 Formulations for the treatment of arhritis conditions |
| 04/26/2006 | EP1648483A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 04/26/2006 | EP1648482A2 Use of a cosmetic or pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins |
| 04/26/2006 | EP1648474A2 Methods and pharmaceutical compositions for healing wounds |
| 04/26/2006 | EP1648473A1 Single dose fast dissolving azithromycin |
| 04/26/2006 | EP1648472A2 Stable oral compositions of azithromycin monohydrate |
| 04/26/2006 | EP1648471A2 Methods for the treatment of male and female sexual dysfunction |
| 04/26/2006 | EP1648470A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor |
| 04/26/2006 | EP1648469A2 Antiglucocorticoids for the treatment of catatonia |
| 04/26/2006 | EP1648468A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 04/26/2006 | EP1648467A1 Process for preparing particles containing an antiviral |
| 04/26/2006 | EP1648466A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 04/26/2006 | EP1648465A1 Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 04/26/2006 | EP1648463A2 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 04/26/2006 | EP1648461A2 Muscarinic acetylcholine receptor antagonists |
| 04/26/2006 | EP1648459A1 Sir2 regulation |
| 04/26/2006 | EP1648457A2 Piperidine derivatives as melanocortin-4 receptor agonists |
| 04/26/2006 | EP1648456A1 Use of 3,7-diazabicyclo¬3,3,1|nonane compounds for the treatment and/or prophylaxis of arrhythmic events in male human patients |
| 04/26/2006 | EP1648455A2 Anaplastic lymphoma kinase modulators and methods of use |
| 04/26/2006 | EP1648454A1 Cci-779 lyophilized formulations |
| 04/26/2006 | EP1648453A1 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes |
| 04/26/2006 | EP1648451A2 Fluconazole capsules with improved release |
| 04/26/2006 | EP1648450A1 Medicaments containing derivatives of aryl (or heteroaryl) azolylcarbinols |
| 04/26/2006 | EP1648449A2 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 04/26/2006 | EP1648448A1 Chemical compounds |
| 04/26/2006 | EP1648442A1 Semi-solid systems containing azetidine derivatives |
| 04/26/2006 | EP1648441A1 Emulsifying systems containing azetidine derivatives |
| 04/26/2006 | EP1648440A1 Semi-solid formulations for the oral administration of taxoids |
| 04/26/2006 | EP1648439A2 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| 04/26/2006 | EP1648438A1 (-)-hydroxycitric acid for controlling inflammation |
| 04/26/2006 | EP1648437A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 04/26/2006 | EP1648436A1 Ambroxol for treating epilepsy |
| 04/26/2006 | EP1648435A1 Ambroxol for treating tinnitus |
| 04/26/2006 | EP1648434A1 Ambroxol for treating chronic nociceptive pains |
| 04/26/2006 | EP1648433A1 Substituted 2-aminotetralin for the treatment of depression |
| 04/26/2006 | EP1648432A1 Use of rotigotine for the treatment of depression |
| 04/26/2006 | EP1648431A1 Novel use of a polyamine-poor composition for the production of a medical human food |
| 04/26/2006 | EP1648430A1 Treatment of premature ejaculation |
| 04/26/2006 | EP1648429A2 Hexameric porphobilinogen synthase as a target for the development of antibiotics and herbicides |
| 04/26/2006 | EP1648428A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 04/26/2006 | EP1648427A2 Compositions and methods including a recombinant human mab that promotes cns remyelination |
| 04/26/2006 | EP1648426A2 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 04/26/2006 | EP1648423A2 Tablets containing ambroxol |
| 04/26/2006 | EP1648422A2 Treatment and preventi0n of cardiovascular events |
| 04/26/2006 | EP1648421A2 Orally dissolving films |
| 04/26/2006 | EP1648417A2 Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 04/26/2006 | EP1648416A2 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| 04/26/2006 | EP1648413A2 Pharmaceutical compositions of short-acting sedative hypnotic agent |
| 04/26/2006 | EP1648408A1 Azepine derivatives as pharmaceutical agents |
| 04/26/2006 | EP1648407A2 Antibiotic product, use and formulation thereof |
| 04/26/2006 | EP1648406A2 Uses and formulations for transdermal or transmucosal application of active agents |
| 04/26/2006 | EP1648394A1 Method for accelerated administration of carotenoid mixtures in serum and tissues |
| 04/26/2006 | EP1648390A2 Compositions containing melon extracts |
| 04/26/2006 | EP1648386A2 Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
| 04/26/2006 | EP1648382A2 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| 04/26/2006 | EP1648378A2 Antimycosic nail varnish |
| 04/26/2006 | EP1648376A2 Novel dermatological composition |
| 04/26/2006 | EP1648232A2 Method of treating hit patients with argatroban |
| 04/26/2006 | EP1572622B1 use of levalbuterol L-tartrate in the production of a metered dose inhaler |
| 04/26/2006 | EP1534708B1 Purine derivatives and their use as antiproliferative agents |
| 04/26/2006 | EP1492524B1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours |
| 04/26/2006 | EP1473996B1 Formulations comprising triazoles and alkoxylated amines |
| 04/26/2006 | EP1465852A4 Synthesis of combretastatin a-2 prodrugs |
| 04/26/2006 | EP1448281A4 Therapeutic coating for an intravascular implant |
| 04/26/2006 | EP1435916B1 Powder processing with pressurized gaseous fluids |
| 04/26/2006 | EP1421377B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 04/26/2006 | EP1414802B1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 04/26/2006 | EP1414467B1 Topical treatment for mastalgia |
| 04/26/2006 | EP1409485B1 Immunomodulating compounds |
| 04/26/2006 | EP1408953B1 Carbamate compounds for use in preventing or treating bipolar disorder |
| 04/26/2006 | EP1399144B1 Carbamate compounds for use in preventing or treating anxiety disorders |
| 04/26/2006 | EP1379520B1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| 04/26/2006 | EP1359979B1 Anti cancer combination of substituted pyrroles and paclitaxel |
| 04/26/2006 | EP1320710B1 Drying method for selectively removing volatile components from wet coatings |
| 04/26/2006 | EP1313509B1 Treatment of tumors with acetylenes disubstituted with an heteroaromatic group and a substituted thiochromanyl group in combination with other anti-tumor agents |
| 04/26/2006 | EP1309592B1 Substituted pyrazoles |
| 04/26/2006 | EP1294689B1 Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt |
| 04/26/2006 | EP1294240B1 Compositions and methods for body weight management |
| 04/26/2006 | EP1259226B1 Anaesthetic formulations |
| 04/26/2006 | EP1255535B1 Controlled release pharmaceutical composition containing tramadol hydrochloride |
| 04/26/2006 | EP1244454B1 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 04/26/2006 | EP1210348B9 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 04/26/2006 | EP1207756B1 Use of spinosad or a formulation comprising spinosad |
| 04/26/2006 | EP1187918B1 Tek antagonists |
| 04/26/2006 | EP1185666B1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production |
| 04/26/2006 | EP1155121B1 Compositions and methods for modulating serum cholesterol |
| 04/26/2006 | EP1153922B1 Heterodiazinone derivatives |
| 04/26/2006 | EP1109553B1 Use of cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases of the head and neck |
| 04/26/2006 | EP1094055B1 Novel vinylbenzene derivatives |
| 04/26/2006 | EP1066036B1 Agents with serotonin-related activity for the treatment for sleep apnea |
| 04/26/2006 | EP1059304B1 Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient |
| 04/26/2006 | EP1053313B1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences |
| 04/26/2006 | EP0977562B8 Methods and compositions for delivery of taxanes |